Literature DB >> 19622457

Azithromycin reduces tumor necrosis factor-alpha production in lipopolysaccharide-stimulated THP-1 monocytic cells by modification of stress response and p38 MAPK pathway.

S Ikegaya1, K Inai, H Iwasaki, H Naiki, T Ueda.   

Abstract

Macrolide antibiotics are known to have a variety of immunomodulatory effects in addition to antimicrobial activity, but the mechanisms of immunomodulation are still unclear. We investigated in vitro the effect of azithromycin on tumor necrosis factor alpha (TNF-alpha) production in lipopolysaccharide (LPS)-stimulated THP-1 cells, a human monocytic cell line, and compared the results with those for other macrolides, minocycline and ofloxacin. In the presence of LPS, treatment with azithromycin (AZM) resulted in a significant decrease in LPS-induced TNF-alpha production compared to that with other antimicrobial agents. the results of phosphorylation of three MAPKs, ERK, JNK and p38, indicated that the phospho-p38 level was reduced by AZM. Ikappab-alpha, an inhibitor of NFkappab, was not disrupted by the antibiotics. LPS-induced TNF-alpha release from THP-1 cells was inhibited in the presence of KNK437, a potent 70-kDa heat shock protein (HSP-70) inhibitor. Interestingly, the induction of HSP-70 by LPS was attenuated with the concurrent addition of AZM in the cells. AZM was found to restrain TNF-alpha production by monocytes at least in part by modifying the HSp-70 and p38 related signaling pathways to LPS stimulation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622457     DOI: 10.1179/joc.2009.21.4.396

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  9 in total

1.  Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells.

Authors:  De-Quan Li; Nan Zhou; Lili Zhang; Ping Ma; Stephen C Pflugfelder
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

Review 2.  Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?

Authors:  Tapan Kumar Mohanta; Pietro Arina; Nanaocha Sharma; Paola Defilippi
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

3.  Randomized controlled trial on immunomodulatory effects of azithromycin in children with steroid-dependent nephrotic syndrome.

Authors:  Happy Sawires; Hanan Abdelaziz; Heba Mostafa Ahmed; Osama Botrous; Michael Agban
Journal:  Pediatr Nephrol       Date:  2019-05-15       Impact factor: 3.714

4.  High throughput screening of small molecule libraries for modifiers of radiation responses.

Authors:  Kwanghee Kim; Robert Damoiseaux; Andrew J Norris; Leena Rivina; Kenneth Bradley; Michael E Jung; Richard A Gatti; Robert H Schiestl; William H McBride
Journal:  Int J Radiat Biol       Date:  2011-03-14       Impact factor: 2.694

5.  Oral antimycobacterial therapy in chronic cutaneous sarcoidosis: a randomized, single-masked, placebo-controlled study.

Authors:  Wonder P Drake; Kyra Oswald-Richter; Bradley W Richmond; Joan Isom; Victoria E Burke; Holly Algood; Nicole Braun; Thyneice Taylor; Kusum V Pandit; Caroline Aboud; Chang Yu; Naftali Kaminski; Alan S Boyd; Lloyd E King
Journal:  JAMA Dermatol       Date:  2013-09       Impact factor: 10.282

Review 6.  Pathogen- and host-directed anti-inflammatory activities of macrolide antibiotics.

Authors:  Helen C Steel; Annette J Theron; Riana Cockeran; Ronald Anderson; Charles Feldman
Journal:  Mediators Inflamm       Date:  2012-06-21       Impact factor: 4.711

7.  Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity.

Authors:  F Ratzinger; H Haslacher; W Poeppl; G Hoermann; J J Kovarik; S Jutz; P Steinberger; H Burgmann; W F Pickl; K G Schmetterer
Journal:  Sci Rep       Date:  2014-12-11       Impact factor: 4.379

8.  Azithromycin does not improve disease severity in acute experimental pancreatitis.

Authors:  Sebastian Weis; Mario Heindl; Tania Carvalho; Elisa Jentho; Jana Lorenz; Ines Sommerer; Joachim Mössner; Albrecht Hoffmeister
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

Review 9.  IL-17A in human respiratory diseases: innate or adaptive immunity? Clinical implications.

Authors:  Dominique M A Bullens; Ann Decraene; Sven Seys; Lieven J Dupont
Journal:  Clin Dev Immunol       Date:  2013-01-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.